← Back to Clinical Trials
Recruiting Phase 2 NCT04600089
Ketamine in Patients Undergoing TEVAR Procedures Receiving NCI
Trial Parameters
Condition Descending Aortic Dissection
Sponsor Sam Tyagi
Study Type INTERVENTIONAL
Phase Phase 2
Enrollment 30
Sex ALL
Min Age 18 Years
Max Age 90 Years
Start Date 2020-12-08
Completion 2027-08
Interventions
SalineKetamine
Brief Summary
The objective of this study is to identify the opioid-sparing effects, and pain-reduction potential of low dose, sub-dissociative ketamine on patients undergoing thoracic endovascular aortic repair (TEVAR) procedures receiving naloxone continuous infusion (NCI).
Eligibility Criteria
Inclusion Criteria: * willing to give informed consent * scheduled for elective thoracic aorta repair or thoracoabdominal aortic repair * requires naloxone continuous infusion for spinal prophylaxis Exclusion Criteria: * allergy to ketamine, acetaminophen, or fentanyl * diagnosis of schizophrenia * history of hydrocephalus or central nervous system mass * incarcerated individuals * pregnant or lactating individuals